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Available online 19 April 2013Abstract Efficient homing/mobilization of human hematopoietic stem/progenitor cells to/from bone marrow niches enhances
their therapeutic efficacy. Additionally, homing is dependent on cell source andmay bemodulated by prior ex vivo cell expansion.
Here, we describe a novel application of a 3-dimensional time-lapse method for assessing trafficking of individual human cord
blood CD133+ hematopoietic stem/progenitor cells in vitro, using the key chemokine CXCL12 as a paradigm. This newmethodology
allows distinction between chemotactic responses (displacement of center of mass and the forward migration index of the cells),
and chemokinetic responses such as total cell path traveled in any direction (accumulated distance) and cell velocity in a
3-dimensional matrix. Other key advantages of this novel assay over existing assays include the ability to assess individual cell
migration over times comparable to in vivo homing and rapid mobilization assays (18–24 h) and to directly compare the strength or
response of individual hematopoietic progenitor cells to different or competing stimuli and small molecule inhibitors in a single
assay prior to analyses in vivo. Importantly, using this method, our results demonstrate definitively that CXCL12 regulates the
chemotactic responses of human cord blood CD133+ cells, but not their random migration or chemokinesis.
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Open acces1. Introduction
Directed cell migration (chemotaxis) towards a stimulus is a
well defined function ofmanymammalian and non-mammalian
cells and is vital throughout embryonic and postnatal life
(Petrie et al., 2009). A key example is the homing or migration
of hematopoietic stem/progenitor cells (HSPCs) to specific
microenvironmental niches, where their fate is determined
(Bianco, 2011; Lawal and Calvi, 2011; Mazo et al., 2011;
Mercier et al., 2011; Nagasawa et al., 2011; Calderón and
Boehm, 2012; Park et al., 2012) or mobilization from theses under CC BY-NC-ND license.
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(Kolonin and Simmons, 2009; Shiozawa and Taichman, 2010;
Mohty and Ho, 2011; Psaila et al., 2012). Importantly, in the
clinical setting, prior manipulation or expansion of HSPCs can
compromise or enhance their homing or migratory capacities
and this can affect transplant outcomes (Aljitawi, 2012). This
is particularly pertinent for cord blood where HSPC content is
limited, engraftment and hematological reconstitution are
delayed compared to bone marrow or mobilized peripheral
blood, one cord blood unit will engraft in preference to
another in double cord blood transplants, and expansion/
manipulation ex vivo prior to transplant is used to reduce
delayed engraftment (Dahlberg et al., 2011; Nagasawa
et al., 2011; Petropoulou and Rocha, 2011; Watt, 2011;
Aljitawi, 2012; Broxmeyer, 2012; Christopherson et al.,
2012; Csaszar et al., 2012; Ramirez et al., 2012).
The CXC chemokine, CXCL12, is a key chemo-attractant
for HSPC homing to bone marrow, also regulating HSPC
motility, homing to, and retention, survival, and prolifer-
ation in this niche (Peled et al., 1999; Dar et al., 2006;Watt and
Forde, 2008; Sharma et al., 2011; Bonig and Papayannopoulou,
2013). The cognate receptors for CXCL12 are CXCR4 and CXCR7,
although the latter is poorly expressed on human HSPCs
(Hartmann et al., 2008; Sun et al., 2010). However, where
expressed on other cells, CXCR7 is thought to act as a decoy
receptor or co-receptor for CXCR4 (Naumann et al., 2010;
Sun et al., 2010). CXCL12/CXCR4 deficient mice demonstrate
defects in hematopoietic, immune, circulatory and central
nervous systems (Zou et al., 1998; reviewed in Watt and Forde,
2008). Co-operation and cross talk between CXCL12/CXCR4,
other receptors/proteins, and signaling molecules are thought
to fine tune cellular responses and/or specificity for microen-
vironmental niches (Forde et al., 2007; Christopherson et al.,
2012; Schiraldi et al., 2012).
The gold standard for determining efficient HSPC homing to
bone marrow niches is their subsequent hematological recon-
stitution following transplantation in humans (Dahlberg et al.,
2011; Ramirez et al., 2012), or, as surrogates, in immunode-
ficient mice or non-human primates (Goessling et al., 2011;
Larochelle et al., 2012). Similar models are used to assess the
efficacy of mobilizing agents (Hoggatt and Pelus, 2011; Bonig
and Papayannopoulou, 2013). However, surrogate assays are
time consuming and costly and do not discriminate between
direct effects on HSPCs nor indirect mechanisms mediated by
bone marrow niche elements. An initial homing/migration
assay ex vivo, which reduces animal usage and allows
refinement of pre-transplant protocols would make screening
of expansion/manipulation/mobilization protocols more effi-
cient and provide essential insights into mechanisms. Although
current transwell migration end-point assays (Toetsch et al.,
2009) measure cell migration towards CXCL12, these simply
give a percentage of cellsmigrating across amembrane towards
a stimulus.
We have developed a novel reproducible in vitro homing/
migration assay using 3D μ-slide chemotaxis chambers from
Ibidi GmbH and timelapse microscopy to track individual
human HSPCs and have used CXCL12 as a paradigm. This allows
the user to compare chemotactic and chemokinetic effects of
a stimulus on HSPC homing/migration, as well as observing
individual cells during the migratory process. Importantly,
using this newmethodology, we have definitively demonstrat-
ed, in contrast to previous assumptions that chemokines alterboth chemotactic and chemokinetic responses simultaneously
(Entschladen et al., 2005), that CXCL12 regulates human
umbilical cord blood (UCB) CD133+ HSPC chemotaxis but not
chemokinesis. Furthermore, we use this assay to compare
the chemotactic and chemokinetic responses of UCB CD133+
cells after an 8 day expansion on a cell-free nanofiber scaffold
in defined cytokine cocktails.
2. Materials and methods
2.1. Cell collection, isolation and culture
Human UCB units were collected with written informed
pre-consent and ethical approval from Oxford and Berkshire
National Research Ethical Committees, and studies conducted
with approval of the NHSBT research committee. Mononuclear
cells from individual or pooled UCB units were isolated by
density gradient centrifugation on lymphocyte separa-
tion medium 1077 (PAA Laboratories, Pasching, Austria;
density b 1.077 g/ml) (Forde et al., 2007) before CD133
immunomagnetic bead selection (Miltenyi Biotec, Bergisch
Gladbach, Germany) (Forde et al., 2007). Cell purity was
assessed by flow cytometry (Forde et al., 2007; Zhou et al.,
2012). In nonexpansion experiments, pooled or individual
freshly harvested or cryopreserved CD133+ cells were cultured
at 5 × 105 cells/ml in StemSpan serum-free medium (Stem
Cell Technologies, Grenoble, France) containing 100 ng/ml
interleukin-6 (IL-6), 20 ng/ml thrombopoietin (TPO),
100 ng/ml stem cell factor (SCF), and 100 ng/ml FLT3 ligand
(R&D Systems, Minneapolis, MN, USA) in 6–12 well tissue
culture plates at 37 °C for 24 h prior to use (Forde et al., 2007).
2.2. Flow cytometry
CD133+ cells were incubated with FcR block and the
relevant antibodies (mouse (m) anti-human PE- or APC-
CD133/2 (293C3), APC- or PerCP-CD34 (AC136 or 8G12
respectively) (all from Miltenyi Biotec), APC- or PeCy5-
CXCR4 (12G5; BD Biosciences, San Jose, CA, USA), APC-
CD45 (HI30; BD Biosciences), or relevant isotype controls
(PE- or APC-mIgG2b-PE, APC- or PerCP-mIgG2a (Miltenyi
Biotec), APC- or PeCy5-mIgG2a or APC-mIgG1-APC (BD Bio-
sciences)) Forde et al., 2007; Zhou et al., 2012), DAPI (1:50,000
dilution, Invitrogen Ltd., Paisley, Scotland) was added as a
viability stain before cells were analyzed on a BD LSR II flow
cytometer using the BD FACSDiva 6 software program (both
from BD Biosciences) (Forde et al., 2007; Zhou et al., 2012).
2.3. Expansion of human UCB CD133+ cells
Nanex nanofiber plates (Arteriocyte Inc., Cleveland, Ohio,
USA) were kindly provided by or purchased from Cambridge
Bioscience (Cambridge, England) and used as the scaffold to
expand human UCB CD133+ cells. The conditions developed by
Arteriocyte (Nanex HSC serum free expansion media with the
undisclosed Nanex cytokines) were defined as standard Nanex
conditions. Other conditions used were the Nanex HSC
expansion media with 100 ng/ml SCF, Flt-3 ligand, IL-6 and
20 ng/ml TPO (R&D Systems; defined as Nanex with SCF,
Flt-3 ligand, IL-6 and TPO), and Nanex HSC expansion media
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Biotec) as well as 100 ng/ml SCF, Flt-3 ligand, IL-6 and
20 ng/ml TPO (defined as Nanex with IGFBP2 and Angptl5).
UCB CD133+cells freshly isolated as above or used after
cryopreservation were suspended in Nanex medium without
cytokines for 4 h before seeding onto the Nanex nanofiber
plates (3 × 103 cells/3 ml in 6 well Nanex plates) in specified
media. After 8 days in culture, cells were collected by pipetting
and a 1 min trypsinization prior to determining viable total
nucleated cell (TNC) counts and the proportions of CD133, CD34
and CD45 positive cells. After expansion, CD133+ cell double
re-purification was carried out using CD133+ immunomagnetic
beads as above, the purity assessed by flow cytometry and the
chemotactic and chemokinetic ability of the re-purified cells
determined using the 3D μ-slide chemotaxis assay described
below.
2.4. Final chemotaxis assay
The 3D chemotaxis μ-slide (Ibidi GmbH, Munich, Germany),
StemSpan media (Stem Cell Technologies) and beveled pipette
tips (Grenier Bio-One, GmBH Frickenhausen, Germany) were
pre-equilibrated for 24 h in a 37 °C incubator. After culture,
UCB CD133+ cells were washed in StemSpan media to remove
cytokines and re-suspended at 3 × 105 cells/100 μl in cold
bovine collagen I gel solution, comprising 20% (v/v) bovine
collagen I gel (5 mg/ml) in α-MEM medium (both from
Invitrogen Ltd.). Six microliter of the collagen gel containing
cell suspension was quickly seeded into the central chamber
(the observation area) of the 3D chemotaxis μ-slide
(Fig. 1A(a)). The slide was then covered with the lid, and
incubated in a humidified incubator at 37 °C upside-down for
1 h until the collagen I gel had set. The reservoirs either side of
the observation chamber were then filled slowly using a
beveled pipette tip with up to 70 μl serum free StemSpan
media (control media; Stem Cell Technologies) or chemo-
attractant media comprising StemSpan media plus CXCL12
(Peprotech, tebu-bio, Peterborough, England) in order to
establish a CXCL12 gradient over the observation area
(Fig. 1A(b)). Where appropriate, the small molecule CXCR4
antagonist, AMD3100 (Sigma-Aldrich Co. Ltd., Gillingham,
England), was added to these reservoirs. The filling channels
were plugged to prevent evaporation and the slide(s) secured
on a Prior Proscan II controlled motorized stage in a 37 °C
humidified heat chamber surrounding the Nikon Eclipse TE300
microscope (Nikon UK Ltd., London, England).
2.5. Data capture and analyses
Data were captured with a Hamamatsu ORCA-ER camera using
SimplePCI automated image capture camera device software
(Hamamatsu Photonics UK Ltd.,WelwynGardenCity, England).
Cell migration was imaged by timelapse microscopy (Nikon
Eclipse TE300 microscope) and photographs taken at regular
intervals (3–5 min) at ×4magnification for up to 22 h. The data
were exported as multipage TIFF files to enable manual cell
tracking using the Image J ‘Manual Tracking’ plug-in
(rsbweb.nih.gov/ij/; Ibidi GmbH) and the Image J ‘Chemo-
taxis and Migration Tool’ plug-in (Ibidi GmbH) used to
quantitate data. The first frame of the movie (time point 0)
was printed and 45–50 cells were selected randomly beforevisualizing the entire movie sequence throughout the
observation chamber. These selected cells were then tracked
individually again in random order until a minimum of 30 viable
cells, which did not divide during the experiment, had been
tracked. Experiments were repeated between 3 and 8 times.
The software was also used to derive trajectory plots (Fig. 1B)
and to quantify the various chemotactic or chemokinetic
responses (Fig. 1C) including i) accumulated distance (total cell
path traveled), ii) Euclidean distance (the shortest distance
between cell start and end points), iii) displacement of the
center of mass (COM; average end position of tracked cells), iv)
directionality (the ratio between Euclidean distance and
accumulated distance or the straightness of the path), v)
forward migration index (FMI; the ratio between the net
distance traveled on the relevant axis and the accumulated
distance), and vi) cell velocity.
2.6. Optimizing the chemotaxis assay
Human UCB CD133+ cells were cultured in serum free StemSpan
media (StemCell Technologies) containing 100 ng/ml SCF, Flt-3
ligand, IL-6 and 20 ng/ml TPO (R&D Systems) for 24 h (Forde
et al., 2007) and then washed in StemSpan medium before
commencing the 3D μ-slide chemotaxis assay as described
above. In optimizing the migration conditions for UCB CD133+
cell chemotaxis, different collagen I concentrations (0.5, 1 or
3 mg/ml collagen I gels), different CXCL12 concentrations (0,
0.2, 1 or 2 μg/ml CXCL12), different timepoints (4, 10, 18 and
22 h), different AMD3100 concentrations (0, 1 and 10 μM) and
pooled versus non-pooled UCB CD133+ cells were tested.
2.7. Statistical analysis
As the data were non-parametric, as determined using the
Shapiro–Wilk and D'Agostino and Pearson omnibus normality
tests and the F test to compare variances (Prism, GraphPad
Software Inc., La Jolla, CA, USA), the Mann Whitney test was
used to determine if significant where appropriate. When data
parameters were correlated, using paired data from indepen-
dent experiments, the linewas fitted using linear regression and
the Spearman's rank test was used to determine the correlation
coefficient using Prism software (www.graphpad.com/prism/
prism.htm). The rs value displayed the goodness of fit, while the
p value determined whether the slope was significantly
different from 0. For the chemotaxis assay, the Rayleigh test
was used to assess if data were significantly inhomogeneously
distributed in any direction when pwas b0.05. Unless otherwise
stated, raw data and median or means and SEM are shown for
n ≥ 3 independent experiments andwith *p b 0.05, **p b 0.01,
and ***p b 0.001 being significant to highly significant.
3. Results
3.1. Optimization and validation of the 3D μ-slide
chemotaxis assay for human UCB CD133+ cells
To establish and validate the 3D μ-slide chemotaxis assay,
freshly isolated or cryopreserved and thawed human UCB
CD133+ HSPCs cultured for 24 h prior to use in serum free
media containing SCF, Flt-3 ligand, IL-6 and TPOwere analyzed
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culture, cells were 94.0% ± 2.0 CD133+, and essentially all
expressed cell surface CXCR4 (Supplementary Fig. 1).
3.1.1. Matrix, chemokine concentration and timecourse
optimization
To optimize the chemotactic protocol, 4 variables were
examined: i) the need for and composition of the 3D matrix,
ii) the CXCL12 concentration, iii) timecourse of migration,
and iv) the use of pooled vs. individual cord blood units. As
migration could not be optimized without a 3D matrix to
hold the CD133+ cells, we tested 3 matrices, matrigel,
methylcellulose and collagen I. Neither matrigel nor
methylcellulose proved practical for this application. In
contrast, collagen I gels (0.5 to 3 mg/ml) supported CD133+
cell movement as illustrated by their accumulated distance
and velocity (Fig. 2A(a,b)). Significant chemotaxis was
observed for all gel concentrations (p b 0.05, Rayleigh test).
Chemotacticmigration towards CXCL12was on average slightly,
although not significantly (p N 0.05), higher with the 3 mg/ml
collagen I gel, but more variable when compared with 0.5 or
1 mg/ml collagen I gels as illustrated for the displacement of
the center ofmass (153.6 μm ± 49.0 versus 94.6 μm ± 19.0 and
113.7 μm ± 1.1 respectively) (Fig. 2A(c)). Chemokinetic migra-
tion was on average lower with the 3 mg/ml collagen I gel, but
more variable when compared with 0.5 or 1 mg/ml collagen I
gels as illustrated for the accumulated distance (916 μm ±
276 versus 1030 μm ± 150 and 1159 μm ± 146 respectively)
(Fig. 2A(a)) and for the velocity (0.66 μm/min ± 0.20 versus
0.82 μm/min ± 0.10 and 0.92 μm/min ± 0.10 respectively)
(Fig. 2A(a)). This variability resulted from a lack of uniformity
in the collagen fiber formation at 3 mg/ml concentrations due
to the speed at which the gel set when less diluted (Fig. 2B).
This was further exemplified when comparing the ranges in the
forward migration index, displacement of the center of mass,
accumulated distance and velocity (Fig. 2A(c,d)). As 1 mg/ml
collagen I gel showed least variability amongst independent
experiments and consistently retained the cells while permit-
ting cell movement, thismatrix and concentrationwere chosen
for our experiments.
The concentration of CXCL12 was optimal at 1 μg/ml
CXCL12, as illustrated for the displacement of center of
mass and the forward migration index (Figs. 3A and B(a,b)).
Interestingly, there was no difference in cell velocity or
accumulated cell distance with increasing concentrations
of CXCL12 (between 0 to 2 μg/ml), indicating that human
UCB CD133+ cell chemokinesis is not influenced by the
presence of CXCL12 (Fig. 3B(c,d)).
When migration was examined as a function of time, the
displacement of the center of mass of CD133+ cells exposed toFigure 1 The 3D μ-slide chemotaxis assay for human cord blood CD13
in StemSpan medium plus SCF, Flt-3 ligand, IL-6 and TPO, (a) human U
into the central 3D μ-slide chamber prior to (b) the addition of StemSp
gradient plus or minus AMD3100 and cells captured by timelapse mi
migrated cells at 22 h minus (a) or plus a CXCL12 gradient (b) or with
lines indicate whether the cells finished their migration path below or
p = 0.17, p = 5.7 × 10−8 and p = 0.054 for (a), (b) and (c) respective
significantly inhomogeneous (i.e. distributed towards the chemoattr
representation of a trajectory plot demonstrating methods for quantit
Figs. 1A and C were captured from themovie describing the assay syste
support/movies/mv25/).CXCL12 increased linearly over 4–18 h before beginning to
plateau (Figs. 4A and B(f)). The forwardmigration index of cells
in the presence of CXCL12 plateaued between 4 and 10 h
(Fig. 4B(h)). While the accumulated distance increased linearly
over time, the largest increase in cell velocity occurred during
the first 4 h of the assay (0 to 0.71 ± 0.14 μm/min). The
accumulated distance and velocity increases observed for the
CD133+ cells over time were independent of a CXCL12 gradient
(Fig. 4B(a to d)). CD133+ cell migration towards CXCL12 in the
3D μ-slide assay was compared for pooled or individual cord
blood units, and although individually variable, no significant
difference in the median chemotactic or chemokinetic mea-
sures was observed (Supplementary Fig. 2).
3.1.2. CXCL12 influences human UCB CD133+ cell chemo-
taxis but not chemokinesis
The final validated procedure (Fig. 1) unless otherwise specified
involved culturing humanUCB CD133+ cells for 24 h in StemSpan
serum-free medium with SCF, Flt-3 ligand, IL-6 and TPO,
washing to remove cytokines and re-suspending cells at
3 × 105 cells/100 μl in a cold collagen I gel prior to seeding
onto the observation area of 3D μ-slide and adding 0 or 1 μg/ml
CXCL12 to opposing reservoirs. Then, each chamber was
photographed at 3–5 min intervals using timelapse microsco-
py for up to 22 h. Supplementary Movie 1 shows representative
trajectory plots of the chemotactic response of 30 randomly
selected individual UCB CD133+ HSPCs towards 1 μg/ml CXCL12
over 22 h. Fig. 5A(a–c) illustrates a significant difference over 8
independent experiments in chemotaxis towards CXCL12
(1 μg/ml) versus 0 μg/ml CXCL12 as determined by the
Rayleigh test, displacement of center of mass and forward
migration index. Individual experimental p values as deter-
mined by the Rayleigh test were between 6 × 10−3 to 6 × 10−9
with CXCL12 and 0.16 to 0.69 without CXCL12. Interestingly,
there was no significant difference in cell velocity (1.0 μm/min
± 0.1 vs 1.1 μm/min ± 0.1) or accumulated distance (1258 μm
± 94 vs 1389 μm ± 91) with or without CXCL12 (Fig. 5A(e,d)),
indicating that CD133+ cell chemokinesis is not influenced by
the presence of CXCL12.
The different parameters were compared to each other
using a Spearman's rank correlation analysis to ensure that the
measures used were valid and accurately represented the
movement of the cells. Forward migration index and displace-
ment of the center of mass were highly correlated (Fig. 5B(a)).
Directionality and forward migration index were also highly
correlated as the forward migration index measures overall
chemotactic efficiency, and directionality the straightness of
the cell path (Fig. 5B(b)). Similarly, displacement of the center
of mass correlated with directionality (Fig. 5B(c)). Velocity and
accumulated distance were highly correlated as the further the3+ hematopoietic stem/progenitor cells. (A) After 24 hour culture
CB CD133+ cells in a collagen I gel solution (1 mg/ml) were seeded
an serum free medium alone (C0) or with a 1 μg/ml CXCL12 (C100)
croscopy at 3–5 minute intervals. (B) Trajectory plots illustrate
CXCL12 in the presence of 10 μM AMD3100 (c). The red and black
above their starting point on the x axis. Rayleigh test p values of
ly indicate that the distribution of the cell end points was only
actant) in the presence of CXCL12 alone (b). (C) Diagrammatic
ating chemotactic and chemokinetic parameters. The diagrams in
m (MV_25_chemotaxis.flv) on the Ibidi website (http://ibidi.com/
Figure 2 The effects of collagen I gel concentrations on CD133+ cell migration in the 3D μ-slide assay. (A) After 24 hour culture of
human UCB CD133+ cells in StemSpan medium and SCF, Flt-3 ligand, IL-6 and TPO, cells were suspended in 0.5 mg/ml, 1 mg/ml or
3 mg/ml collagen I gel solutions and seeded into the central chamber of the 3D chemotaxis μ-slides. A chemokine gradient was
established using 1 μg/ml CXCL12. The cells were imaged over 22 h by timelapse microscopy migration and analyzed using Image
J manual tracking software and the chemotaxis and migration tool plug in for (a) accumulated distance, (b) velocity, (c) displacement
of the center of mass and (d) forward migration index. Values are means ± SEM (n ≥ 3independent experiments). Variability amongst
independent experiments was increased when 3 mg/ml collagen I gels were compared with 0.5 or 1 mg/ml collagen I gels. This is
exemplified when comparing 1 mg/ml and 3 mg/ml collagen I gels respectively for the ranges in the accumulated distance (1012 μm
to 1451 μm vs. 350 μm to 1467 μm respectively), velocity (0.77 to 1.16 vs. 0.27 to 1.18 μm/min respectively), displacement of center
of mass (111.80 to 115.43 vs. 26.94 to 256.20 μm respectively) and forward migration index (0.100 to 0.110 vs. 0.060 to 0.220
respectively). (B) Microscopic images (×4 magnification) of CD133+ cells in (a) 0.5 mg/ml, (b) 1 mg/ml and (c) 3 mg/ml collagen 1
gels after seeding into the central chamber of the 3D chemotaxis μ-slide and demonstrating the lack of uniformity of collagen I fibers
with 3 mg/ml collagen I gels.
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(Fig. 5B(d)). A negative, highly significant correlation was
observed between the p values for the Rayleigh test and both
the displacement of center of mass and forward migration
index (Fig. 5B(e,f)). This confirmed that the Rayleigh test was a
useful tool for defining chemotaxis, as the greater the
displacement of center of mass or forward migration index,
the more significant the p value. No significant correlations
were seen between the displacement of the center of mass
and velocity or accumulated distance. Neither was thereany correlation between p values from the Rayleigh test
and velocity or accumulated distance.3.2. AMD3100 blocks CD133+ cell chemotaxis but
not chemokinesis of human UCB CD133+ cells
To demonstrate that migration could be modulated by
specific small molecule inhibitors, the CXCR4 antagonist
AMD3100 (Goessling et al., 2011) was added to the 3D μ-slide
Figure 3 The CD133+ cell chemotactic response to increasing concentrations of CXCL12. Human UCB CD133+ cells cultured in StemSpan
mediumwith SCF, Flt-3 ligand, IL-6 and TPO for 24 h were encapsulated in 1 mg/ml collagen I gel and seeded into the central chamber of
the 3D chemotaxis μ-slides. 0 μg/ml, 0.2 μg/ml, 1 μg/ml or 2 μg/ml CXCL12 were added to create a chemokine gradient. The cells were
imaged over 22 h by timelapse microscopy and analyzed using Image J manual tracking software and the chemotaxis and migration tool
plug-in. (A) Representative trajectory plots after CD133+ cells were exposed to differing concentrations of CXCL12. The red and black
lines indicate whether the cells finished their migration path below or above (towards differing CXCL12 concentrations) their starting
point on the x axis. Rayleigh test p values were p = 0.16, p = 6.1 × 10−5, p = 4.0 × 10−10 and p = 1.0 × 10−7 respectively for figures
(a)–(d) indicating that the distribution of the cell end points was only significantly inhomogeneous (i.e. distributed towards the
chemoattractant) in the presence of CXCL12 (b)–(d) and that this was most significant with 1 μg/ml (c). (B) shows the quantitative data
for (a) displacement of center of mass (257.8 μm ± 112.9 for 1 μg/ml compared to no CXCL12 of 48.8 μm ± 8.9), (b) forward migration
index (0.18 ± 0.05 for 1 μg/ml compared to no CXCL12 of 0.02 ± 0.00), (c) cell velocity and (d) accumulated distance as a function of
CXCL12 concentration. Values are means ± SEM for n = 3 independent experiments.
713Novel chemotaxis for individual CD133+ cellschemotaxis reservoir and shown to be inhibitory (Fig. 6). With
CXCL12 and no AMD3100, the p values for the Rayleigh test
were significant (p b 0.01 for all experiments), however with
addition of 1 μmand 10 μmAMD3100, theywere not significant
(p N 0.05; Fig. 6(e)). With AMD3100 addition, there was a
significant decrease in the displacement of the center of mass
and forward migration index towards CXCL12 (Fig. 6(a,b);
Supplementary Movies 1–3). Interestingly, there was no
reduction in chemokinesis in terms of the accumulated distance
nor cell velocity in the presence of CXCL12 without AMD3100 or
in the presence of 1 μM or 10 μM AMD3100 (Fig. 6(c,d)).3.3. Expanded human UCB CD133+ cells retain their
chemotactic response towards CXCL12
In Supplementary Fig. 3, we demonstrate using Nanex
nanofiber scaffolds in serum free Nanex medium that SCF,
Flt-3 ligand, IL-6 and TPO promoted a 65 ± 4 fold expansion
of freshly isolated human UCB CD133+ HSPCs. We therefore
compared the effects on CD133+ cell chemotaxis of expanding
identical aliquots of human UCB CD133+ cells in such cultures
(this time after cryopreservation and thawing) containing SCF,
Flt-3 ligand, IL-6 and TPO without or with the addition of
100 ng/ml IGFBP2 and 100 ng/ml Angptl5. Cells before expan-
sion were 88.4% ± 2.8 CD133+, 96.5% ± 3.0 CD45+ and 93.8% ±2.6 CD34+. After 8 days of culture, the expanded cells without
andwith IGFBP2 and Angptl5 were respectively 85.0% ± 4.3 and
86.6% ± 3.0 viable, 96.8% ± 3 and 96.6% ± 3.3 CD45+, and
38.7% ± 10.2 and 37.7% ± 9.7 CD34+CD133+ (Fig. 7A(a)). Total
nucleated cell (TNC) expansion was 148 ± 49 and 209 ± 64 fold
for the cells cultured with SCF, Flt-3 ligand, IL-6 and TPO
without or with IGFBP2 and Angptl5 respectively (Fig. 7A(b)),
while CD34+ cell expansion was 107 ± 46 and 147 ± 61 fold
respectively (Fig. 7A(b,c)). Although there was some variability
in the TNC and CD34+ cell expansion in three independent
experiments, CD133+ cell expansion was more consistent
amongst experiments (Fig. 7A(b,c)). There was a 52 ± 6 and
73 ± 6 fold increase in CD133+ cells and a 52 ± 4 and 73 ± 2
fold increase in CD133+CD34+ cells without and with IGFBP2
and Angptl5 respectively (Fig. 7A(b,c)). Thus, the addition
of IGFBP2 and Angptl5 enhanced CD133+ and CD34+CD133+
cell numbers approximately 1.5 fold over 8 days.
The cultured human UCB CD133+ cells were assessed for
their ability to migrate to CXCL12 using the 3D μ-slide
chemotaxis assay. After CD133+ cell purification, CD133+
cell purities were respectively 92.8% ± 3.3 and 94.5% ± 1.2
(Fig. 7B(c,d)) and recoveries were respectively 51.8% ± 9.9
and 43.8% ± 12.8 for cells expanded in Nanex media with
SCF, IL-6, TPO and Flt-3 ligand without or with IGFBP2 and
Angptl5. CXCR4 expressionwas present on essentially all CD133+
cells (Fig. 7B(g,h)). Figs. 7C and D demonstrate an enhanced
Figure 4 CD133+ cell chemotaxis and chemokinesis as a function of time. Human UCB CD133+ cells were cultured in StemSpan
medium with SCF, Flt-3 ligand, IL-6 and TPO for 24 h, encapsulated in 1 mg/ml collagen I gel and seeded into the central chamber of
the 3D chemotaxis μ-slides, prior to adding 0 μg/ml or 1 μg/ml CXCL12 to form a chemokine gradient as illustrated in Fig. 1. Cell
migration was imaged for 22 h by timelapse microscopy and tracked and analyzed using Image J manual tracking software and the
chemotaxis and migration tool plug-in after 4, 10, 18 and 22 h. (A) shows representative trajectory plots (a) 4 h, (b) 10 h, (c) 18 h and
(d) 22 h (the blue cross shows the displacement of the center of mass) of cells exposed to 1 μg/ml CXCL12. The red and black lines
indicate whether the cells finished their migration path below (towards 1 μg/ml CXCL12) or above their starting point on the x axis.
The Rayleigh test indicate that the distribution of the cell end points was significantly inhomogeneous at all time points
(i.e. distributed towards the chemoattractant) in the presence of CXCL12 (p = 4.0 × 10−3, p = 2.9 × 10−5, p = 6.7 × 10−7 and
2.0 × 10−8 for (a)–(d) respectively. (B) shows the quantitative data for (a,b) accumulated distance, (c,d) velocity, (e,f) displacement
of the center of mass, and (g,h) forward migration index, of cells exposed to 0 μg/ml CXCL12 (a,c,e,g) or 1 μg/ml CXCL12 (b,d,f,h)
respectively. Values are means ± SEM for n = 3 independent experiments.
714 E.E. Pepperell, S.M. Wattchemotactic response towards CXCL12 when additionally
stimulated with Angptl5 and IGBP2 (although not reaching
statistical significance in 3 experiments), and no signifi-
cant change in chemokinetic responses (p N 0.5). Thus,
the expansion did not compromise CD133+ cell chemotaxis
to CXCL12 when compared to unexpanded cells in earlier
experiments.4. Discussion
The key advantages of this novel timelapse assay over existing
transwell assays include the ability i) to measure the chemo-
tactic and chemokinetic responses of individual non-adherent
progenitor cells for periods comparable to published in vivo
homing assays (18–24 h) (Larochelle et al., 2012), ii) to
distinguish chemotactic from chemokinetic responses by
individual cells to stimuli over time, parameters which are
difficult to define in standard transwell assays (Toetschet al., 2009), iii) to directly compare the strength or response
to different or competing stimuli in a single assay, iv) to assess
whether stimuli act directly onHSPCswithout the complication
of niche influences observed in vivo (Shiozawa and Taichman,
2010; Bianco, 2011; Calderón and Boehm, 2012; Park et al.,
2012; Psaila et al., 2012), v) to assess small molecule inhibitor
effects on individual HSPCs in this multiwell platform for
multiple cell migration parameters, and vi) to assess migratory
responses of HSPCs in a 3D rather than a 2D environment. A
disadvantage is that the substantial data generated in this new
assay required manual tracking. When we used Wimasis
semi-automated tracking (Khoo et al., 2011), the Wimasis
algorithm was unable to follow cells for the duration of the
experiment and therefore requires further development.
Using identical CD133+ cells to initiate each assay, the
number of human UCB CD133+ cells migrating in the 3D μ-slide
chemotaxis assay was 3–5 fold higher than those migrating in
the transwell assay (25.9 + 9.2% means + SEM for n = 3 inde-
pendent experiments). Since the transwell migration results are
Figure 5 CXCL12 induces human cord blood CD133+ hematopoietic stem/progenitor cell chemotaxis but not chemokinesis. Human
UCB CD133+ cells were cultured in StemSpan medium with SCF, Flt-3 ligand, IL-6 and TPO for 24 h, encapsulated in 1 mg/ml collagen I
gel and seeded into the central chamber of the 3D chemotaxis μ-slides, prior to adding 0 μg/ml or 1 μg/ml CXCL12 to form a
chemokine gradient. (A) The results of 8 independent experiments are displayed as median values (horizontal bar) for individual
experiments (scatter plots). Cell migration was tracked using Image J manual tracking software for 22 h and chemotactic and
chemokinetic parameters quantified with the chemotaxis and migration tool plug-in for (a) the Rayleigh p value, (b) displacement of
the center of mass (blue cross in Figs. 1B and C), (c) forward migration index, (d) directionality, (e) velocity and (f) accumulated
distance. Interestingly, there were significant differences in chemotaxis between the chambers containing medium alone and those
containing CXCL12, with the following respective changes (mean ± SEM) in Rayleigh values (0.336 ± 0.073 vs. 0.001 ± 0.001; p =
0.0002), displacement of center of mass (10.82 ± 11.25 vs. 189.00 ± 44.26; p = 0.0002) and forward migration index (0.015 ± 0.008
vs. 0.126 ± 0.024; p = 0.0004) over 8 independent experiments, but no significant difference in cell velocity or accumulated distance
without or with a CXCL12 gradient (p = 0.7128 and p = 0.2345 respectively). Statistics for chemotactic and chemokinetic data were
calculated using the Mann–Whitney test with *p b 0.05, **p b 0.01 and ***p b 0.001. (B) Correlation between (a) displacement of the
center of mass and forward migration index, (b,c) directionality and forward migration index or displacement of the center of mass,
(d) velocity and accumulated distance, and (e,f) p values of the Rayleigh test and displacement of the center of mass or forward
migration index in the presence of a CXCL12 gradient in the 3D μ-slide chemotaxis assay was determined using Spearman's rank
correlation coefficient, rs. p values of *p b 0.05, **p b 0.01, and ***p b 0.001 show significance for n = 15 independent experiments.
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Figure 6 AMD3100 inhibits chemotaxis but not chemokinesis. HumanUCBCD133+ cells were cultured in StemSpanmediumwith SCF, Flt-3
ligand, IL-6 and TPO for 24 h, encapsulated in 1 mg/ml collagen I gel and seeded into the central chamber of the 3D chemotaxis μ-slides,
prior to adding 1 μg/ml CXCL12 to form a chemokine gradient with or without AMD3100. Histograms Illustrate the effect of adding 0, 1 μMor
10 μM AMD3100 with 1 μg/ml CXCL12 for the chemotactic or chemokinetic responses of forward migration index (A) and displacement of
the center of mass (B) or velocity (C) and accumulated distance (D). Controls contained media alone. Values are means ± SEM for n ≥ 3
independent experiments. Notably, with the addition of AMD3100, there was a significant decrease in the Rayleigh test p values (E), in
displacement of the center of mass (mean ± SEM values of 126.5 μm ± 21.1 for no AMD3100 to 24.7 μm ± 18.1 for 1 μM AMD3100 and
7.5 μm ± 10.6 for 10 μM AMD3100) and in forward migration index (mean ± SEM values of 0.11 ± 0.02 with no AMD3100 and 0.01 ± 0.01
for 1 μM AMD3100 and 0.01 ± 0.01 for 10 μM AMD3100) towards CXCL12 compared to absent AMD3100 (p b 0.05 for all). There was no
reduction in chemokinesis in terms of the accumulated distance (1167 ± 79 μm) nor the velocity (1.0 ± 0.0 μm/min) of cells without or
with AMD3100 addition (1200 ± 179 μm and 1.0 ± 0.1 μm/min respectively for 1 μM AMD3100 and 1255 ± 100 μm and 1.0 ± 0.1 μm/min
respectively for 10 μM AMD3100; p N 0.5). Statistics were calculated using the Mann–Whitney test with *p b 0.05 being significant.
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Kim and Broxmeyer, 1998; Kollet et al., 2002; Forde et al.,
2007), the differences may be explained by 3D migration in
collagen I versus 2Dmigration on fibronectin, different endpoint
times and in situ tracking ofmigrating cells rather than the need
to recover cells prior to analyses. Renkawitz and Sixt (2010)
have described plasticity in cell migratory mechanisms in vitro
when 3D is comparedwith 2D environments. Using the 3D assay,
we demonstrated increasing cell migration towards CXCL12
over 18 to 22 h of between 67% and 97% of the cells, indicating
that these cells do not stop responding to CXCL12 in the 3D
environment within the 4–6 hour timeframe used for the 2D
transwell assay. In developing this new assay, the weak
adhesion of human UCB HSPCs to ECM coated surfaces did
not, in our hands, provide an optimal platform for use of the
Ibidi 2D μ slide chemotaxis assay. When we attempted to
reproduce the 2D μ-slide chemotaxis assay of Grassinger et al.
(2009), where the cells were not encapsulated in a matrix, we
found that the cells were not easily retained in the observation
chamber when the reservoirs were filled. While HSPCs are
known to bind to fibronectin through α4β1 and α5β1 integrins
(Ulyanova et al., 2011 and references therein), they do not
express significant levels of the collagen receptors, α1β1,
α2β1, α3β1, α10β1, and α11β1 (Humphries et al., 2006) and
hence this may also affect the mechanics of each assay.Importantly using CXCL12/CXCR4 interactions as a paradigm
for other factors and receptors, we demonstrated that CXCL12
is required for chemotaxis, but not chemokinesis of human UCB
CD133+ HSPCs in the absence of niche elements, and that the
CXCR4 antagonist, AMD3100, inhibits chemokine sensing but not
the ability of these cells to move randomly. This disputes
previous suggestions by Entschladen et al. (2005) that chemo-
taxis does not occur without increasing chemokinesis, and
provides a means to study in much more detail the effect of
chemokines such as CXCL12 on inducing chemotaxis and/or
chemokinesis in leukemic cell lines and primary leukemic stem/
progenitor cells (Zepeda-Moreno et al., 2012). Other studies
examining the chemotactic and chemokinetic movement of
other cell types, such as the HT-1080 carcinoma cell line and
human umbilical vein endothelial cells (HUVECs) towards an FCS
gradient (Zengel et al., 2011), have demonstrated using Ibidi
chemotaxis slides that chemokinetic migration as measured by
cell velocity and accumulated distance can be influenced by the
presence of a stimulus.
We also examined the effects of short term (8 day)
expansion of human UCB CD133+ cells on a cell free nanofiber
scaffold in the presence of cytokines on their chemotactic and
chemokinetic responses to CXCL12. Using identical humanUCB
CD133+ cells to initiate the cultures, a greater and consistent
expansion of CD133+CD34+ cells was also seen after 8 days in
Figure 7 Chemotaxis after cord blood CD133+ cell expansion. Human UCB CD133+ cells were cultured on Nanex nanofiber scaffolds
in Nanex serum free HSC expansion medium containing SCF, Flt-3 ligand, IL-6 and TPO without (black histograms) or with
(gray histograms) IGFBP2 and Angptl5 for 8 days prior to (A) flow cytometric analyses of surface markers or cell viability or
(B) reselecting CD133+ cells and analyzing (C) their chemotactic or chemokinetic responses to CXCL12. The red and black lines
indicate whether the cells finished their migration path below or above (towards 1 μg/ml CXCL12) their starting point on the x axis.
The Rayleigh p values indicate that there was a significant inhomogeneous distribution of the cells following expansion in either
cocktail towards CXCL12 in the presence of a CXCL12 gradient ((a) p = 3.6 × 10−5 and (b) p = 2.4 × 10−8). A(a) shows the % of
expanded cells expressing CD133, CD34 and CD45. A(b) shows the fold expansion of TNC and CD133 and CD34 single and dual positive
subsets after 8 days of culture. A(c) shows the relative cell numbers generated after 8 day cultures for TNC and each specified cell
subset, initiated with 3 × 106 TNC which were 88.4 ± 2.8% CD133+. Values are means + SEM for n = 3 experiments. D shows a
comparison of chemotactic and chemokinetic responses of UCB CD133+ cells after 8 days expansion with specific cytokines compared
to 24 hour treatment with specific cytokines.
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Comparison of Chemotactic and Chemokinetic Responses to CXCL12 after Cytokine Stimulation
Parameter Day 8 Nanex nanofiber 
scaffold expansion
+SCF, Flt-3 ligand, IL-6, TPO*
Day 8 Nanex nanofiber 
expansion scaffold
+SCF, Flt-3 ligand, IL-6, 
TPO, IGFBP2, Angptl5*
Day 1 StemSpan medium 
culture
+SCF, Flt-3 ligand, IL-6, 
TPO**
CXCL12
(µg/ml)
0 1 0 1 0 1
Forward 
Migration 
Index 
0.027+0.024 0.160+0.025 0.027+0.024 0.173+0.061 0.014+0.009 0.139+0.024
Displacement 
of Center of 
Mass (µm)
32.4+14.7 205.9+60.8 32.4+14.7 242.1+18.6 19.0+11.3 182.6+46.0
Velocity 
(µm/min)
0.97+0.10 0.97+0.10 0.97+0.10 1.00+0.10 1.07+0.08 1.04+0.11
Accumulated 
Distance
(µm)
1215+158 1210+186 1215+158 1177+143 1427+71 1314+91
*n=3 independent experiments using the same batches of UCB CD133+ cells:
** n= 8 independent experiments
D
Figure 7 (continued).
718 E.E. Pepperell, S.M. Wattour cultures with the addition of IGFBP2 and Angptl5 to SCF,
Flt-3 ligand, IL-6 and TPO than without (averaging 73 versus 52
fold respectively). Drake et al. (2011) using Angptl5 and
IGFBP2 together with SCF, TPO and FGF-1 in StemSpan media
without a nanofiber scaffold, demonstrated on average a 21
fold increase in CD133+CD34+ cells after 10 days and a much
more variable response between expansion rates than observed
here, suggesting that the Nanex scaffold and media used here
could be enhancing expansion by greater than 2–3 fold over a
shorter period of time. Although Drake et al. (2011) showed
that CD133+CD34+ cell number correlates with repopulating
ability in NSGmice, we have yet to demonstrate this. However,
when we isolated the CD133+ cells from our expansion cultures
and tested their chemotactic response to CXCL12 in the 3D
μ-slide chemotaxis assay, we found a non-significant trend
towards enhanced chemotaxis but not chemokinesis with the
addition of IGBP2 and Angptl5, with these cells continuing to
express CXCR4. The 8 day culture did not compromise the
chemotactic ability of the expanded CD133+ cells compared to
our other experiments where CD133+ cells were cultured for
24 h in SCF, Flt-3 ligand, IL-6 and TPO.
5. Conclusions
In conclusion, this novel 3D μ-slide chemotaxis assay provides a
much improved tool, enabling the user to observe the exact
response over time of individual HSPCs to chemotactic versuschemokinetic stimuli in vitro, while using fewer cells than
standard transwell migration assays. This is an important
advance when analyzing rare stem/progenitor cell popula-
tions from donors or for use in patients. This 3D μ-slide
chemotaxis assay has the added advantage that it can
be further extended by using fluorescence microscopy
to provide detailed information on heterogeneous popula-
tions as well as to examine cell morphology, interactions,
division and death, and all cells can be tracked if required.
This will complement studies in vivo aimed at the better
development of protocols to enhance HSPC expansion,
engraftment and mobilization.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2013.04.006.
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